Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 10Active not recruiting 7Withdrawn 1Terminated 1Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 19Breast Neoplasms 12Lung Neoplasms 10Brain Neoplasms 9Glioblastoma 7Neoplasm Metastasis 6Neoplasms 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Pancreatic Neoplasms 4Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Mycosis Fungoides 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Gliosarcoma 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Sezary Syndrome 2Rectal Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroendocrine Tumors 2

Interventions

pembrolizumab 20Carboplatin 14Cyclophosphamide 12atezolizumab 11Paclitaxel 10Albumin-Bound Paclitaxel 8Capecitabine 7Nivolumab 6130-nm albumin-bound paclitaxel 6spartalizumab 5fludarabine 5Taxes 5Gemcitabine 5talazoparib 4bintrafusp alfa protein, human 4avelumab 4Cisplatin 4sacituzumab govitecan 3olaparib 3entinostat 3Leucovorin 3Ipilimumab 3Immunoglobulin G 3Drug Therapy 3Doxorubicin 3Docetaxel 3Biopsy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3trilaciclib 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Triple Negative Breast Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
5 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡